Laguna Blends, Inc. (OTC: LAGBF) is a network marketing company focused on the generation of sales through independent affiliates. Leveraging innovative tools and technologies, the company’s affiliates are able to build international businesses from their own homes while effectively capitalizing on the performance of some of the world’s most rapidly expanding, in-demand markets. Affiliates also have the ability to recruit new affiliates, expanding Laguna’s reach into the $3.4 trillion global wellness industry.

Laguna’s leading product category focuses on the unique nutritional health benefits offered by hemp-based beverages. Caffe, the company’s first product, is an instant, “just add water” hot coffee beverage that’s infused with both whey and hemp protein, giving it a powerful protein punch. Through the commercialization of Caffe, Laguna is tapping into the expansive global market for coffee.

According to reports from the Coffee Association of Canada (CAC), coffee is consumed by a larger proportion of adults than any other beverage, excluding water. Approximately two-thirds of adult Canadians drink coffee on a daily basis, according to the CAC, with coffee drinkers consuming, on average, 3.2 cups per day. When combined with the strong performance of the global hemp industry, which was valued at nearly $500 million in 2012 by the Hemp Industries Associates, the market potential for Caffe moving forward is tremendous.

In early March, Laguna launched sales of its protein coffee beverage through 135 independent affiliates throughout the United States and Canada. In less than a week, the company’s affiliate base grew to include 278 independent members, marking a growth rate of 105 percent. Stuart Gray, Laguna’s president and CEO, explained the company’s strong start in a recent news release.

“Laguna has launched its business with a high level of interest from independent affiliates residing in the USA and Canada. The demand for high quality, functional beverage products throughout the United States and Canada, coupled with a viable business opportunity, has attributed to the spike in affiliate interest,” he stated. “In addition, the positive feedback on Laguna’s first product to market, Caffe, has been fantastic.”

In addition to Caffe, Laguna has been granted approval from Health Canada for the commercialization of Pro369, a single serving, “on-the-go” hemp protein that’s available in four flavors, including chocolate banana, mixed berry, vanilla caramel and tropical powder. Pro369 is water soluble, meaning that it can be mixed directly into water or milk, and it can also be blended into shakes and smoothies for an added boost of omega 3-6-9 and ginseng.

On March 3, Laguna set the stage for additional expansion of its product line when it signed a letter of intent with Robert Lamberton Consulting regarding the development of a “Limitless functional beverage brain health and memory coffee” product. Under the terms of the LOI, all hard costs associated with the development of the product will be billed to Robert Lamberton Consulting. The two parties intend to enter into a formal research and development agreement outlining the details of the relationship before April 15, 2016.

For more information, visit www.lagunablends.com

We are apt to scoff at stories of virgin birth, and the term itself is something of an oxymoron, since the virgin usually has had some ‘knowledge’ of a male progenitor. Many of the classical Greco-Roman heroes, like Hercules, who were the product of a virgin birth, were fathered by gods, as was the Christ, according to Christian dogma. But virgin birth or, at least, reproduction that takes place in the absence of fertilization, called parthenogenesis, occurs in nature all the time, both in plants (e.g. roses and orange trees) and animals (some kinds of ants, bees and wasps). Now, researchers have discovered ways of engendering parthenogenesis in mammals.

Early work on stem cells involved human embryos and, consequently, gave rise to ethical debate and controversy that threatened further research efforts. But in a ground-breaking paper titled ‘Nonhuman Primate Parthenogenetic Stem Cells’ (http://dtn.fm/3aP4i), published in 2003, Kent Vrana et al, wrote about their stem cell work using monkeys and reported that ‘stem cells were created via parthenogenetic activation of eggs’. This use of non-human cells provided a route out of the moral dilemma. Then, building on the insights of Vrana and his colleagues, a team at the privately-held Stemron Corporation of Rockville, Maryland, led by David Wininger reported in ‘Human Embryonic Stem Cell Lines Derived from Discarded Embryos’ (http://dtn.fm/o8ZcS) that it had ‘grown parthenogenetic human embryos to the blastocyst stage at which stem cells can be obtained’ and that ‘cells taken from one of the embryos survived for a few days’.

An April 2003 story in New Scientist titled ‘Virgin birth method promises ethical stem cells’ (http://dtn.fm/e2eWb), commenting on the Wininger breakthroughs, discusses how this is possible. Unfertilized eggs have two complete sets of chromosomes and during fertilization one set is discarded. ‘But an electric or chemical shock can make the egg develop as if fertilized and retain the extra set’. In parthenogenesis, an unfertilized egg keeps two sets of chromosomes and begins developing as if it had been fertilized and thus ‘produces embryos that could never become human beings’. The destruction of ‘these embryos to obtain stem cells would avoid the ethical concerns that have led to restrictions or bans on embryonic stem cell research in many countries.’

One area involving stem cells that shows remarkable promise is in the treatment of Parkinson’s disease. According to the Harvard Stem Cell Institute HSCI), Parkinson’s is ‘associated with the death of cells in a part of the brain… which produces the neurotransmitter dopamine’. Researchers at the HSCI have ‘orchestrated the transformation by biologically reprogramming the mature skin cells into induced pluripotent stem cells, and then encouraging the stem cells to become dopaminergic neurons. Neurons were also made from skin cells collected from individuals with genetic mutations associated with high risk for Parkinson’s disease’.

International Stem Cell Corporation’s (OTCQB: ISCO) UniStemCell for Parkinson’s has completed the Food & Drug Administration’s (FDA) Investigational New Drug (IND) phase, and the company announced recently that it had received authorization to initiate a phase I/IIa clinical trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) for the treatment of Parkinson’s Disease.

The phase I/IIa clinical study, which will be performed at the Royal Melbourne Hospital in Melbourne, Australia, is a dose escalation safety and preliminary efficacy study of ISC-hpNSC intracranially transplanted into patients with moderate to severe Parkinson’s disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson’s disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals to evaluate the safety and biologic activity of ISC-hpNSC. PET scans will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC will be evaluated using various neurological assessments.

In announcing the study, Russell Kern, PhD, ISCO’s executive vice president and chief scientific officer commented, “We are the first company in the world to conduct clinical trials of human pluripotent stem cells based product for the treatment of Parkinson’s disease. We believe the outcome of the study will produce findings in-line with our preclinical studies, where we demonstrated not only safety of our proprietary neural stem cells, but also their functional efficacy. The cells were able to successfully integrate into the brain and provide a significant increase of dopamine levels in the nigrostriatal system”

This is welcome news. As the Harvard Stem Cell Institute reminds us: ‘Approximately one to two percent of the population over the age of sixty receives a diagnosis of Parkinson’s disease, although scientists believe that may be a very conservative estimate (and) at least one million Americans are currently known to be living with the condition.’

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Immune Therapeutics, Inc. (OTCQB: IMUN) centers its works on applying its patented immunotherapy to fight chronic diseases, such as cancer, which affect people of all ages and races all over the world. Leveraging the body’s natural immune system, the company’s product line and immunotherapy technologies are engineered to enhance treatment for those suffering with HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.

One of IMUN’s promising treatments is Low Dose Naltrexone (LDN), or Lodonal, as it is known on a global scale. Lodonal has its origins in the FDA-approved 50mg Naltrexone. Initially known to treat opiate dependencies, the Immune Therapeutics patented treatment, which covers a wide range of indications, is currently used as an immune modulator. Lodonal /LDN works by boosting levels of endorphins (peptides produced in the brain and adrenal glands). These natural peptides are very effective modulators of the immune system. When patients take Lodonal, it attaches to opioid receptors in the brain and immune cells and temporarily blocks endorphins signaling the body in order to increase endorphin production. The increased endorphin production facilitates the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells. Lodonal is also effective in preventing immune system over activity, the core of autoimmune disorders, and reduces the release of inflammatory and neurotoxic chemicals in the brain.

New York physician Dr. Bernard Bihari, who has studied immune responses primarily in HIV/AIDs patients, has produced a three-point mechanistic approach to the use of LDN showing the following three distinct increases within the immune system. The first increase is within met-enkephalin (an endorphin produced in large amounts in the adrenal medulla) and endorphin in the blood stream. The second increase occurs within the number and density of opiate receptors on the tumor cell membranes, thereby making them more responsive to the growth-inhibiting effects of the already present levels of endorphins, which in turn induces apoptosis in the cancer cells. Third, increases are stimulated within absolute numbers of circulating cytotoxic T cells (CD8+/TH1) and natural killer cells (“NK cells”), as well as NK cell activity.

IMUN focuses on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS, autoimmune diseases, and immune disorders in the United States. Currently, the company is developing IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by stimulating a patient’s immune system against infectious diseases, autoimmune diseases, immune disorders, and tumor cells. The company is headquartered in Orlando, Florida.

Learn more by visiting www.immunetherapeutics.com

Let us hear your thoughts: Immune Therapeutics, Inc. Message Board

Earlier today, Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) announced an upcoming investors conference call, which is scheduled for Tuesday, March 22, 2016, at 2:00PM EST.

During the call, Steve Barber, the company’s executive chairman and chief executive officer, will expand upon Oakridge’s recent press announcements. In particular, Barber is expected to offer more details on the company’s recently unveiled strategic business alliance agreement with Tokyo-based trading house Sojitz Group, outlining what the new agreement means to both Oakridge and its shareholders. Other topics set to be discussed during the call include an update on revenue forecasts for the first quarter of 2016, the electric interstate truck project and the recent release of the Liberty Series motorcycle battery at the Daytona Beach Bikefest. Barber will also provide an update on the progress of shipments of Oakridge’s Pro Series golf car batteries.

The Call-In Number to access Tuesday’s conference call is +1 712-775-7035. The Access Code is 684304#.

“We started 2016 in full manufacturing mode and have continued to ramp up as the first quarter has progressed,” Barber stated in this morning’s news release. “We are currently shipping production product in the golf car and low speed electric vehicle markets; the radio controlled unmanned vehicles and drones markets; the motorcycle starter motor markets; and a number of very special custom applications. It is a very exciting time at Oakridge!”

Since the start of 2016, Oakridge has made tremendous progress toward expanding its foothold in the global stored energy market. Last month, the company powered a successful demonstration of Maritime Tactical Systems, Inc.’s Man-Portable Tactical Autonomous Systems (MANTAS) with a custom battery specially designed to function in a number of strenuous applications – including naval fleet protection, mine warfare, port and harbor security patrol, anti-piracy and search and rescue. Later in the same week, Oakridge announced plans to supply batteries to Freedom Trucking’s fully electric interstate truck propulsion system.

In early March, the company continued to build on its recent progress when it presented its state-of-the-art, ‘Made in the USA’ Pro-Series lithium ion golf car battery systems at the Orlando PGA Merchandise Show, one of the biggest annual golf industry conventions in the world. Oakridge followed up on this presentation with the commercial introduction of its lithium ion motorcycle batteries at the 75th annual Daytona Beach Bikefest, which concluded on March 14.

For more information, visit www.oakridgeglobalenergy.com

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

In December 2015, the U.S. Department of Energy published the sixth edition of its annual report on the fuel cell industry. Issued by its Fuel Cell Technologies Office, the report is punned State of the States: Fuel Cells in America 2015. As expected, it is a wealth of information on the state of the industry, and it notes that Dominovas Energy Corporation (OTCQB: DNRG) is the only fuel cell company that has been named a Private Sector Partner (PSP) in a multi-stakeholder partnership sponsored by the United States government.

The report opens with a sunny prognosis: ‘The fuel cell industry – which surpassed $2.2 billion in annual sales in 2014 – continues to grow and is generating impressive benefits in a number of ways.’ An increasing number of states are supporting development of the industry because of the promise of additional jobs and increased tax revenues. Fuel cells offer many benefits. They ‘bolster the electric grid, provide reliable and resilient power, reduce emissions, reach remote and rural parts of the country, and utilize domestic sources of energy, including natural gas.’ Fuel cells are also gaining significance as a source of back-up power, particularly in keeping critical communication networks and data centers up and running, but also as a technology ‘to provide primary or backup power to ensure constant power through major storms, or other disruptive events’. From an industry perspective, fuel cells will boost exports and help America regain lost ground in manufacturing.

States are providing tax and other incentives for fuel cells. For example, the New York State Energy Research and Development Authority (NYSERDA) has provided financial incentives to support the installation and operation of continuous duty fuel cell systems in New York State, with up to $1 million available for fuel cell systems rated larger than 25kW. A fuel cell system that size will meet the energy needs of the typical household comfortably, and the federal government is lending its support as well. The IRS offers a Fuel Cell Motor Vehicle Credit ‘…if you purchase a fuel cell motor vehicle that is propelled by power that is derived from one or more cells that convert chemical energy directly into electricity. You must purchase the vehicle before January 1, 2017 and begin driving it in the year in which you claim the credit. The base credit is $4,000 for a fuel cell motor vehicle weighing up to 8,500 pounds and $10,000 – $40,000 for heavier vehicles.’ There is also the Business Energy Investment Tax Credit (ITC) under which a tax credit of 30 percent of the purchase price of a fuel cell system can be applied against income tax payable in the year that the unit is placed into service.

Many large businesses are seizing the fuel cell advantage. ‘Wal-Mart is the largest fuel cell customer for material handling equipment (MHE), deploying the technology to power more than 2,800 forklifts at warehouses in Ohio, Pennsylvania, New York, Illinois, Indiana and Minnesota, with more sites on the way. The company also uses stationary fuel cells to generate power for 44 Wal-Mart (NYSE: WMT) and Sam’s Club retail sites in California and Connecticut. Then there’s food service product distributor, Sysco (NYSE: SYY), which has expanded its fuel cell fleet to more than 800 fuel cell-powered forklifts operating at seven of its warehouses in California, Massachusetts, New York, Texas, Virginia, Pennsylvania, and Michigan. Over the last few years, AT&T (NYSE: T) has deployed fuel cells to provide primary power to almost two dozen data and call centers, as well as backup power to hundreds of cell phone towers in multiple states.’

Dominovas Energy Corporation is positioned to generate and sell electricity on a multi-megawatt scale by way of the commercial production of its Solid Oxide Fuel Cell (SOFC) technology, known as the RUBICON™. The RUBICON™, by design, will be a highly efficient, combustion-less, and virtually pollution free energy source that will provide electricity to power a wide array of systems, either through distributed power applications (in which power is generated by the user) or to the grid. The technology can be factored and scaled to provide power to entire cities. In principle, a fuel cell is an electrochemical device that operates like a battery. However, unlike a battery, a fuel cell does not require recharging, but refueling. The RUBICON™, as designed, will use fuel, principally hydrogen extracted from natural gas, propane, or other hydro-carbon based fuels along with oxygen extracted from air to produce electricity. The RUBICON™ system will produce energy in the form of electricity and heat as long as there is a constant fuel source. The RUBICON’s™ operation is also quite simple: it has minimal moving parts and operates quietly with low emissions.

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Over-the-counter (OTC) pain medications should be the first choice when trying to tolerate chronic pain. Ultra-addictive, narcotic pain medications produced by big pharma companies are so rampant in today’s world. Nutra Pharma Corp. (OTCQB: NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property portfolio is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

Nutra Pharma’s product pipeline includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company’s Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

One problem with making a pain medication from cobra venom is the supply of cobra venom. Nutra Pharma has completed a series of projects to update and expand the facilities that house the Asian cobras utilized for the production of Nyloxin. Included with these updates was the addition of 100 snakes to the existing milking line to increase venom production in line with upcoming international orders from India and China.

“We are at an amazing inflection point for the Company,” Rik J. Deitsch, Chairman and CEO of Nutra Pharma, stated in a news release. “Over the past few months, we have dramatically reduced costs, paid down debt and recapitalized the share structure of the Company,” he continued. “Now we need to focus on increasing sales for our OTC products, Nyloxin and Pet Pain-Away. This also requires us to scale up our raw material supplies and production facilities. The growth-limiting material for Nutra Pharma is cobra venom, the active ingredient in our OTC products. We need to make sure that we have an adequate supply of validated material to meet our future production needs. With the recently announced expansion into India and China, we realize that we will need to grow exponentially to meet these expected product orders in the coming months. The expansion of the reptile facilities ensures that we can grow apace with the increasing orders.”

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

Dominovas Energy Corp. (OTCQB: DNRG) is resolute about its mission to electrify the world. Using a calculated approach backed by its technical prowess and access to project financing, Dominovas is moving forward with its plans to introduce and deploy technology that will transform the way electricity is delivered on the continent of Africa.

Using a complex set of solutions, Dominovas Energy addresses concerns about toxic carbon emissions, as well as reducing instances of equipment maintenance and inefficiencies. These are pervasive issues linked to power generation from diesel generators, combined-cycle gas-fired turbine power plants and other combustion-centric technologies. These are also major issues that result in increased costs.

After recognizing that alternative energy markets, like those in Africa, have massive potential for growth, Dominovas Energy began focusing its intellectual and financial capital on devising a green energy solution that is reliable, efficient and measurably cleaner than other alternatives. With its proprietary RUBICON™ Solid Oxide Fuel Cell (SOFC) technology, Dominovas Energy is preparing to deploy such a solution in multi-megawatt power generation units worldwide.

Countries and companies have entrusted Dominovas Energy to deliver its 21st century energy solutions and technology, having executed guaranteed multi-MW contracts in the Congo and having received a license to produce electricity in Angola. Last summer, the company publicized the execution of a guaranteed 200MW multi-year Power Provider Agreement (PPA) with the Democratic Republic of the Congo. As a result of the PPA, Dominovas Energy was tasked with providing electricity to the country’s South Kivu Province using its RUBICON™ Solid Oxide Fuel Cell system.

Late in the year, Dominovas Energy made strides in Angola, as well. The Angolan Ministry of Petroleum granted the company an independent Power Producer license that authorizes it to provide clean and reliable electricity to companies within the country’s oil and gas industry. Along with demonstrating the Angolan leadership’s dedication to new technologies, this marked a significant moment for Dominovas Energy: its RUBICON™ system became the first and only fuel cell-based technology solution to have been granted this license in Angola. This substantial accomplishment was also a capstone of the work the Dominovas Energy management team has done to push ahead the commercial proliferation of its SOFC fuel cell technology.

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

With an already impressive portfolio of digital commerce technologies, Alternet Systems, Inc. (OTCQB: ALYI) plans to continue investing in more verticals within the industry. The company looks for innovative solutions to manage digital commerce, information, and payments. These solutions must improve efficiency and quicken the pace of commerce. Alternet also develops predictive data analytics applications for consumers and the telecommunications and financial industries, which are all high growth markets. Predictive analytics, itself a profitable marketing tool, is expected to grow exponentially over the next few years.

Predictive analytics and statistical analysis are based on observed actions in relation to future actions. Analysts choose a dependent variable based on something that has already occurred and compare that variable to other variables that could be related statistically through a predictive software. For example, companies can analyze traits of the customers who have already purchased their product and then see if these traits relate to other consumers. This information then allows companies to “microtarget” their desired audiences with effective marketing strategies. Using predictive analytics saves time and money, because companies only market to those individuals who share similar characteristics to the customers who have already purchased their products.

Alternet plans to offer software that integrates analytics, micro-segments, and automatic marketing technology. Clients will be able to view data across diverse sources about their unique audiences, which can help them develop micro-targeting tactics to push business forward. The software could even provide marketing recommendations.

Predictive analytics and micro-targeting aim to “reach the right people with the right message.” This segment has already gained momentum, with 2015 showing $242 million in funding for startups, as compared to $376 million for all previous years combined. The technology shows no signs of slowing down as the world continues to become more technologically dependent.

Going forward, Alternet stands to gain from these numbers with its strong digital commerce and predictive data analytics applications. The company intends to lead the digital commerce industry by continuously developing and harnessing innovative technology to keep up with the world’s growing demand.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

Before the opening bell, Halitron, Inc. (OTC: HAON) continued to build on what has been a hot start to 2016 through the finalization of its third acquisition of the year. ArchivalMuseumSupplies, a leading direct marketing brand from Plastic Retail Displays, LLC, is now part of the Halitron family of businesses. ArchivalMuseumSupplies targets an expansive customer base – including museums, libraries, archivists and professional photographers – by offering archival-grade storage products, such as metal edge storage boxes, envelopes, sleeves and bags, designed to help preserve valuable contents for an extended period of time.

“ArchivalMuseumSupplies competes in a niche market that has lower risks associated with economic downturns as the product is a staple within the niche archiving community,” Bernard Findley, chief executive officer of Halitron, stated in this morning’s news release. “The brand also opens up the opportunity to evaluate digital archiving based on leveraging the current customer base with new products and services.”

Halitron acquired the ArchivalMuseumSupplies brand for a total purchase price of $635,319, including $119,359 payable in a short term note and $515,960 paid via the issuance of restricted common stock. As part of this transaction, Halitron also acquired related equipment, molds and dies, raw material, finished goods, a customer list totaling more than 128,500 customers, the www.ArchivalMuseumSupplies.com website and a collection of digital artwork files.

ArchivalMuseumSupplies boasts an average order value (AOV) of $130.44, which will increase the company’s AOV by 8.6 percent to $116.98. After merging the ArchivalMuseumSupplies brand with its existing factory infrastructure, Halitron will look to add an additional 35 percent gross profit margin by manufacturing a number of products it sells to end users.

“Halitron, Inc. now owns NDG Holdings Inc., a digital marketing company (acquired Jan ’15), PRD Holdings Inc., a Mexican based factory (acquired Feb ’16), and two niche brands, PiecesInPlaces (acquired Feb ’16) and Archival Museum Supplies (acquired Mar ’16),” continued Findley. “The base business model is in full operations with strong digital marketing, efficient manufacturing, and well-known brands in niche markets.”

With the completion of its sixth acquisition since 2015, Halitron’s management team is actively seeking out additional acquisition candidates to roll into its existing infrastructure. Including its current pipeline of acquisitions, the company is currently on a run rate to generate over $10 million in sales over the next three years.

For more information, visit www.halitroninc.com

Let us hear your thoughts: Halitron, Inc. Message Board

People often cite the popular phrase, “You are what you eat.” It reminds us of the great extent to which diet affects long-term health. Even if we want to eat more wholesome foods, obtaining accurate information at the right time is not always easy. And what about the millions who suffer from food allergies and intolerances? In the U.S., there are about 15 million people who suffer from food allergies. 1 in 13 children are affected and continue to be at risk. A study released in 2013 by the Centers for Disease Control and Prevention (CDC) reported that food allergies among children increased approximately 50 percent between 1997 and 2011. For those who suffer, making the right choices could be a matter of life and death. Now, Content Checked Holdings, Inc. (OTCQB: CNCK) hosts a family of mobile apps that help sufferers of a variety of food allergies, dietary restrictions, or intolerances navigate the minefields of the modern food industry.

At present, Content Checked’s suite of apps includes ContentChecked, MigraineChecked and SugarChecked. ContentChecked, which was its first, is a smartphone application designed for use by those who suffer from food allergies and intolerances. The app allows its users to scan a product’s bar code and determine if it is suitable for the individual. MigraineChecked is a more specialized app that combines research on migraine triggers and their links to food ingredients. An estimated 38 million Americans suffer from migraine and chronic headaches. SugarChecked is another specialized app that identifies added sugars, artificial sweeteners, natural low-calorie sweeteners and sugar alcohols; the user can choose any or all of these four options.

The company’s family of apps provides easy shopping tools for consumers to decipher often-misleading food labels, and receive recommendations for healthier alternative products, by simply scanning the barcodes of grocery store products. Other features include an expansive recipe database with directions and ideas on food preparation for avoiding allergic reactions. Content Checked also maintains a database of allergens and food ingredients that indicates any relationship between the two. Currently, that database has information on more than 200,000 products available in the United States and is updated 24/7 by a team of nutritionists.

In a recent interview (http://dtn.fm/ju0GV) with ceolive.tv, CEO Kris Finstad pointed out the value of that database, which includes information on over 70 percent of food products available on the domestic market. Content Checked, through licensing agreements, has begun making this information available to third parties through cross-promotional partnerships.

Together ContentChecked, MigraineChecked and SugarChecked have had over 2 million downloads, and 66 percent of the apps’ users utilize the tools at least five times per week.

For more information, visit www.contentchecked.com

Let us hear your thoughts: ContentChecked Holdings Inc. Message Board